Monoclonal antibody · Inhibitor of mutant calreticulin (mutCALR) (CALR) · developed by Incyte
INCA033989 is a human IgG1 monoclonal antibody that binds the mutated form of calreticulin (mutCALR) on CALR-mutated CD34-positive hematopoietic stem cells, sparing wild-type calreticulin. By blocking mutCALR complex formation with the thrombopoietin receptor, it suppresses TPO-R signaling and JAK2/STAT activation. It is being studied in essential thrombocythemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07623200 | Phase 3 | Essential Thrombocythemia | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Essential Thrombocythemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.
See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
INCY catalysts and pipeline →